BIIB
53
-2
UPS
41
-4
PSA
55
-3
GE
71
3
EMC
91
-5
ABT
50
2
FFIV
67
3
HUM
48
-4
ORLY
66
16
CMCSA
41
-9
EXPE
72
3
PH
77
2
AVGO
45
3
PWR
71
3
ADSK
63
2
AZO
59
3
MRK
46
-4
IRM
49
2
EW
37
-2
NOV
50
-2
BIIB
53
-2
UPS
41
-4
PSA
55
-3
GE
71
3
EMC
91
-5
ABT
50
2
FFIV
67
3
HUM
48
-4
ORLY
66
16
CMCSA
41
-9
EXPE
72
3
PH
77
2
AVGO
45
3
PWR
71
3
ADSK
63
2
AZO
59
3
MRK
46
-4
IRM
49
2
EW
37
-2
NOV
50
-2
Financhill
Back

Akebia Therapeutics 10K Form

Buy
62

AKBA
Akebia Therapeutics

Last Price:
$3.64
Seasonality Move:
-6.68%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive AKBA News And Ratings

See the #1 stock for the next 7 days that we like better than AKBA

AKBA Financial Statistics

Sales & Book Value

Annual Sales: $160.2M
Cash Flow: $-13.6M
Price / Cash Flow: 0
Annual Sales: $0.09
Price / Book: 38.68

Profitability

EPS (TTM): -0.21000
Net Income (TTM): $-45.3M
Gross Margin: $97M
Return on Equity: 0%
Return on Assets: -19.14%

Akebia Therapeutics Earnings Forecast

Key Akebia Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 12 years for AKBA is 60.56%.
  • The Selling, General & Administrative Expenses for AKBA have been equal to 66.52% of Gross Profit Margin.
  • The Research & Development expenses have been 23.51% of Revenue.
  • The Net Earning history of AKBA is -43.33% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 6 years.

Akebia Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: AKBA
CUSIP: 00972D
Website: akebia.com

Debt

Debt-to-Equity Ratio: 1.89
Current Ratio: 2.23
Quick Ratio: 1.92

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 13.66

AKBA Technical Analysis vs Fundamental Analysis

Buy
62
Akebia Therapeutics (AKBA) is a Buy

Is Akebia Therapeutics a Buy or a Sell?